Slovak health ministry says Sputnik V doses tested in Hungary satisfactory
Reuters
Published May 09, 2021 11:37AM ET
PRAGUE (Reuters) - A Slovakia health ministry spokeswoman said on Sunday a Hungarian lab has confirmed that the first batch of Russia's Sputnik V COVID-19 vaccines sent to Slovakia were satisfactory and the government would discuss the next steps with Russia.
The tests were carried out in Hungary after Russia had requested additional tests in an EU-certified laboratory, saying the Slovaks had not tested them in such a facility. The Slovak government is considering whether to use the Russian shots in the country of 5.5 million that has been hit hard by the COVID-19 outbreak.
The Slovak health ministry's spokeswoman, Zuzana Eliasova, said on Sunday that Slovakia is now waiting for further test results from Russia, which are expected at the end of May.
She did not provide details on what kind of tests were carried out in Hungary or how the results might address any data gaps raised by Slovakia's drug regulator.
Hungary's drug regulator said in April it would help Slovakia examine batches of Russian Sputnik V vaccines that Slovakia had received, and Slovak Health Minister Vladimir Lengvarsky said on Friday the tests were satisfactory.
"Yesterday we received by email from the Hungarian side the results of the tests, which are negative, they are alright," Lengvarsky told reporters on Friday. "In the next round we will communicate with our experts and mainly with the Russian side about the next development in this question.”
To date Russia has not won approval from the EU regulator, the European Medicines Agency, for Sputnik V. So far, Hungary is the only EU country to have begun inoculations with Sputnik V without waiting for EMA approval.
Peer-reviewed late-stage trial results published in The Lancet medical journal in February showed Sputnik V was almost 92% effective.
Russian's RDIF sovereign wealth fund, which markets the Sputnik V vaccine abroad, says the shot's safety and efficacy had been assessed by regulators in 61 countries that approved it for use. The Gamaleya Institute, the vaccine's developer, has said Sputnik V is 97.6% effective against COVID-19 in a "real-world" assessment based on data from 3.8 million people.
"Now the test run by Hungary's National Public Health Center in the EU-certified lab confirms that Sputnik V batch sent to Slovakia meets all safety and other requirements, debunking earlier incorrect Slovak statements to the contrary," a statement, shared on the vaccine's official Twitter account run by RDIF, said.
Slovakia received 200,000 doses in March, part of a deal for 2 million doses, a delivery that caused a political storm and led former Prime Minister Igor Matovic to resign.
The Slovak health ministry authorised the use of Sputnik V as an unregistered drug in March, but asked national drug agency SUKL to evaluate the vaccine before rolling out the so-far unused doses.
Get The News You Want
SUKL concluded that it could not determine the benefits and risks of Sputnik V due to gaps in the data provided by Moscow but said in an opinion in April that Sputnik V passed tests for sterility, clarity, colour, abnormal toxicity and other measures.
German Chancellor Angela Merkel said last month the EMA has not yet received sufficient information about Russia's Sputnik V coronavirus vaccine to approve it but if approval does come soon, Germany will buy it.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.